Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 20/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2747419 | 0.88 | HSD11B1 (0.72) | HSD11B1 | |
| SCHEMBL19248155 | 0.85 | HSD11B1 (0.72) | HSD11B1 | |
| SCHEMBL2754206 | 0.84 | HSD11B1 (0.59) | HSD11B1 | |
| SCHEMBL2745880 | 0.81 | HSD11B1 (1.00) | HSD11B1 | |
| SCHEMBL15520880 | 0.81 | HSD11B1 (0.77) | HSD11B1 | |
| SCHEMBL2748143 | 0.80 | HSD11B1 (1.00) | HSD11B1 | |
| SCHEMBL2748376 | 0.76 | HSD11B1 (0.69) | HSD11B1 | |
| SCHEMBL2747354 | 0.75 | HSD11B1 (1.00) | HSD11B1 | |
| SCHEMBL2747863 | 0.74 | HSD11B1 (1.00) | HSD11B1 | |
| SCHEMBL2748470 | 0.74 | HSD11B1 (1.00) | HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10039772-B2 | Methods and compositions for treating alcohol use disorders | SANNA PIETRO PAOLO (US) | 2018-08-07 | — | — | US | disclosed |
| US-20170232007-A1 | METHODS AND COMPOSITIONS FOR TREATING ALCOHOL USE DISORDERS | SANNA PIETRO PAOLO (US) | 2017-08-17 | — | — | US | disclosed |
| EP-1732904-B1 | DIARYLTRIAZOLES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 | MERCK SHARP & DOHME (US) | 2014-03-19 | — | — | EP | disclosed |
| US-8178546-B2 | Diaryltriazoles as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 | MERCK SHARP & DOHME CORP. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178546-B2 | Diaryltriazoles as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 | MERCK SHARP & DOHME CORP. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20100256387-A1 | DIARYLTRIAZOLES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 | MERCK SHARP & DOHME (US) | 2010-10-07 | — | — | US | disclosed |
| US-20100256387-A1 | DIARYLTRIAZOLES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 | MERCK SHARP & DOHME (US) | 2010-10-07 | — | — | US | disclosed |
| US-20080255216-A1 | Diaryltriazoles as Inhibitors of 11-Beta-Hydroxysteroid Dehydrogenase-1 | MERCK SHARP & DOHME CORP. | 2008-10-16 | — | — | US | disclosed |
| US-20080255216-A1 | Diaryltriazoles as Inhibitors of 11-Beta-Hydroxysteroid Dehydrogenase-1 | MERCK SHARP & DOHME CORP. | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10039772-B2 | Methods and compositions for treating alcohol use disorders | HSD3B1, HSD11B1, HSD3B2 | HSD11B1 2/4885 |
| US-20170232007-A1 | METHODS AND COMPOSITIONS FOR TREATING ALCOHOL USE DISORDERS | HSD3B1, HSD11B1, HSD3B2 | HSD11B1 2/4885 |
| US-20100256387-A1 | DIARYLTRIAZOLES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 | HSD11B1, HSD11B2, HSD3B1 | HSD11B1 1/4885 |
| US-20080255216-A1 | Diaryltriazoles as Inhibitors of 11-Beta-Hydroxysteroid Dehydrogenase-1 | HSD11B1, HSD11B2, HSD17B1 | HSD11B1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.